Work

Atinvicitinib, a novel, second-generation selective JAK1 inhibitor for the treatment of allergic dermatitis and atopic dermatitis in dogs

Year: 2026
Type: article
Abstract: The onset of allergic dermatitis in dogs involves a complex immunological cascade which is largely mediated by the JAK-STAT signalling pathway. Several isolated enzyme and cell-based signalling pathway engagement assays were performed in vitro to evaluate the potency and selectivity of atinvicitinib, a novel second-generation JAK inhibitor. Atinvicitinib inhibited JAK1, JAK2, JAK3, and TYK2 activity in isolated human enzyme assays with IC 50 s of 0.43, 5.9, 1130 and 13.02 nM respectively, demonstrating a greater than 10-fold selectivity for JAK1 over the other JAK enzymes. When evaluated against a panel of 265 human kinases, atinvicitinib displayed a greater than 900-fold selectivity for JAK1. Additionally, when tested at a concentration of 10 µM against a panel of 112 rat, guinea pig, or human enzymes, transporters and receptors, atinvicitinib did not demonstrate stimulatory or inhibitory activity. The signalling of IL-6 (JAK1/JAK2) and EPO (JAK2) in human cell-based pathway engagement assays was inhibited by atinvicitinib with IC 50 s of 41.5 and 456 nM, respectively, consistent with the > 10-fold JAK1 selectivity displayed in isolated JAK enzyme assays. The signalling of JAK1 dependent cytokines involved in inflammation and allergy (IL-4 and IL-13) and pruritus (IL-31) in canine DH82 cells was inhibited by atinvicitinib at IC 50 s between 2.9 and 33.6 nM. These results demonstrate that atinvicitinib selectively inhibits JAK1 enzyme activity in human enzyme and cell-based assays in vitro, and that its potency against canine JAK1 in a canine cell-based system is comparable to that in human cells. While additional complementary studies are warranted, these data indicate the potential of atinvicitinib to selectively inhibit pro-inflammatory (IL-2 and IL-6), pro-allergenic (IL-4 and IL-13) and pruritogenic (IL-31) JAK1-dependent cytokines in canine allergic dermatitis.
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W7234590356
FWCI:
Cites:
Cited by:
Related to: 10